Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner

This article was originally published in The Tan Sheet

Executive Summary

Private labeler will take a "significant restructuring charge" in FY 2001 fourth quarter to cover costs of reengineering initiative that began in July 2000 and was accelerated in the fiscal third quarter ending Dec. 31, Leiner announces Feb. 14. Initiative includes elimination of 500 positions and closure of three facilities; manufacturing operations will be relocated to the firm's OTC facility in Fort Mill, S.C. (1"The Tan Sheet" Nov. 20, 2000, p. 4). Net sales for fiscal Q3 were down 12.7% to $159.5 mil. from the year-ago period; for the nine months, net sales were flat at $454.6 mil

You may also be interested in...



Leiner Restructuring Builds On SKU Reductions, Customer "Rationalization"

Leiner Health Products is cutting approximately 40% of its SKUs as part of a restructuring plan designed to turn around the dietary supplement and OTC drug marketer's ailing financials.

Leiner Restructuring Builds On SKU Reductions, Customer "Rationalization"

Leiner Health Products is cutting approximately 40% of its SKUs as part of a restructuring plan designed to turn around the dietary supplement and OTC drug marketer's ailing financials.

Leiner Restructuring Builds On SKU Reductions, Customer "Rationalization"

Leiner Health Products is cutting approximately 40% of its SKUs as part of a restructuring plan designed to turn around the dietary supplement and OTC drug marketer's ailing financials.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel